Business News

    Botanix Pharmaceuticals (ASX:BOT) completes FDA mid-cycle review meeting for sweat drug

    Article Image

    The FDA (Food and Drug Administration - US) has conducted the mid-cycle review meeting for Sofpironium Bromide, Botanix Pharmaceuticals' (ASX:BOT) lead product which helps with excessive sweating.

    Botanix Pharmaceuticals says no significant issues have been identified by the FDA as a result of their review, and also noted no major clinical safety issues, risk management issues, or advisory board requirements.

    The company also says FDA-indicated future discussions will focus on labeling, clinical outcome assessments, patient instructions, and brand name.

    The planned approval date for Sofpironium Bromide in September 2023 remains on track.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa